Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.
Q4/FY26 results show 19% revenue growth and 31% PAT growth, but these numbers were disclosed in earlier filings. Real story: 13th consecutive record quarter and Plant-6 on track.
— 3 earlier stories on Windlas Biotech Ltd. →What's new
- Revenue grew 19% YoY to ₹904 Cr, crossing ₹900 Cr for the first time.
- Adjusted PAT up 31%; 13th straight quarter of record revenue.
- Plant-6 mechanical completion noted; results widely anticipated.
Why it matters
Windlas delivered a solid year with margin expansion and capital efficiency. But these numbers were already expected after the annual results and buyback filings. The market's reaction is likely muted; the focus now shifts to how Plant-6 capacity converts into FY27 growth.
What we're watching
- Plant-6 ramp-up and its impact on FY27 margins.
- Whether the company can sustain double-digit growth as the base expands.
- Any update on order book or new customer wins in the concall.
The full read
Windlas Biotech's FY26 results are impressive on paper: 19% revenue growth, 31% PAT growth, and a first-time cross of ₹900 Cr in annual revenue. The company also notched its 13th consecutive quarter of record revenue. However, these figures were already disclosed in the annual results and buyback filings, making today's press release confirmatory rather than revelatory. Management's commentary on operational discipline and Plant-6 mechanical completion is positive but not new. For investors, the open question is FY27: can capacity expansion drive incremental growth without margin compression? The market had already priced in FY26; the forward story is what matters now.